Newsroom

CSL released its 2015-2016 Corporate Responsibility Report, which details company performance in key social, environmental and economic priority areas.

Health Canada has approved AFSTYLA, CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.

Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION^® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for the treatment of hemophilia B.

CSL Behring’s RAPID Extension Study data confirms disease-modifying effect of Respreeza^® in patients with AATD.

AEGIS-1 Phase 2b study meets co-primary endpoints of hepatic and renal safety and demonstrates proof of mechanism - results were presented at AHA 2016.

Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for patients with haemophilia A.

One of the world’s top specialty biotherapeutics companies, CSL Behring continues to introduce innovations to address unmet medical needs or enhance current treatments

Many Rare Disease Patients Would Not Have Treatments Available to Them without an Adequate Supply of Human Plasma, and patients call plasma donors "heroes" for their lifesaving contributions.

CSL Behring announced that the Australian Therapeutic Goods Administration (TGA) has approved IDELVION^®[albutrepenonacog alfa] in patients with haemophilia B (congenital factor IX deficiency).

Global biotherapeutics leader CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IDELVION® [Albutrepenonacog Alfa], its innovative, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the prevention of bleeding tendency in patients with factor IX deficiency.

CSL Behring is proud to be a platinum sponsor of the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID) this week in Barcelona

General Counsel Greg Boss of global biotherapeutics leader CSL Limited today accepted the World Recognition of Distinguished General Counsel from the Directors Roundtable in recognition of his professional accomplishments and passion for ethical leadership

CSL Behring is hosting an Expert Forum "Modifying Alpha-1 Antitrypsin Deficiency Related Emphysema" today during the 26th International Congress of the European Respiratory Society (ERS) in London.

The U.S. Food and Drug Administration (FDA) has accepted CSL Behring’s application for its low volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy for treating HAE. Upon FDA approval, CSL830 will be the first and only low volume, subcutaneous, prophylactic treatment option for HAE patients.

CSL Behring today presented data from a Phase III pivotal study of AFSTYLA^® [Antihemophilic Factor (Recombinant), Single Chain] in hemophilia A patients less than 12 years of age at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla.

CSL Behring today announced new data from its Phase III PROLONG-9FP clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for treating hemophilia B.

CSL Behring today announced that the company has named five recipients of the 2016 CSL Behring Professor Heimburger Award for coagulation research at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla.

CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla., July 24 – 28, 2016.

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved the use of Berinert [C1 Esterase Inhibitor (Human)], its therapy for treating Hereditary Angioedema (HAE) attacks, for use in pediatric patients.

CSL Behring announced today at the Peripheral Nerve Society’s Inflammatory Neuropathy Consortium (INC) meeting at the University of Glasgow, Scotland, the winners of its annual Interlaken Leadership Awards.